MOREPENLAB
Invest Now
Morepen Laboratories Share Price
₹73.87 -2.06 (-2.71%)
21 Nov, 2024 14:33
Start SIP in MOREPENLAB
Start SIPPerformance
- Low
- ₹74
- High
- ₹76
- 52 Week Low
- ₹39
- 52 Week High
- ₹101
- Open Price₹76
- Previous Close₹76
- Volume3,760,092
Investment Returns
- Over 1 Month -13.39%
- Over 3 Month + 8.86%
- Over 6 Month + 54.7%
- Over 1 Year + 86.89%
Smart Investing Starts Here Start SIP with Morepen Laboratories for Steady Growth!
Morepen Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 30.8
- PEG Ratio
- 0.2
- Market Cap Cr
- 4,048
- P/B Ratio
- 4.8
- Average True Range
- 4.05
- EPS
- 2.4
- Dividend Yield
- 0
- MACD Signal
- -1.21
- RSI
- 41.24
- MFI
- 39.92
Morepen Laboratories Financials
Morepen Laboratories Technicals
EMA & SMA
Current Price
₹73.87
-2.06
(-2.71%)
- Bullish Moving Average 3
- Bearish Moving Average 13
- 20 Day
- ₹79.72
- 50 Day
- ₹80.03
- 100 Day
- ₹74.72
- 200 Day
- ₹65.24
Resistance and Support
75.77
- R3 79.49
- R2 78.20
- R1 77.06
- S1 74.63
- S2 73.34
- S3 72.20
Morepen Laboratories Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2024-11-11 | Quarterly Results | |
2024-08-12 | Quarterly Results | |
2024-05-21 | Audited Results | |
2024-01-31 | Quarterly Results | |
2023-11-02 | Quarterly Results |
Morepen Laboratories F&O
About Morepen Laboratories
- NSE Symbol
- MOREPENLAB
- BSE Symbol
- 500288
- Chairman & Managing Director
- Mr. Sushil Suri
- ISIN
- INE083A01026
Similar Stocks to Morepen Laboratories
Morepen Laboratories FAQs
Morepen Laboratories share price is ₹73 As on 21 November, 2024 | 14:19
The Market Cap of Morepen Laboratories is ₹4047.7 Cr As on 21 November, 2024 | 14:19
The P/E ratio of Morepen Laboratories is 30.8 As on 21 November, 2024 | 14:19
The PB ratio of Morepen Laboratories is 4.8 As on 21 November, 2024 | 14:19
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.